Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA approves once-daily COPD drug Breo

Theravance Inc. (NASDAQ:THRX) gained $3.63 (12%) to $34.94 on Friday after FDA approved an NDA from partner GlaxoSmithKline plc (LSE:GSK;

Read the full 205 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE